Applied Precision company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

api.com

Founded Year

1986

Stage

Acquired | Acquired

Total Raised

$24M

About Applied Precision

Applied Precision provides imaging, measurement and analysis systems for the life sciences industries and OEM markets.In April 2011, Applied Precision was acquired by GE Healthcare. The valuation of Applied Precision was undisclosed. Other terms of the deal were not released.

Applied Precision Headquarter Location

1040 12th Avenue Northwest

Issaquah, Washington, 98027,

United States

425-557-1000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Applied Precision Patents

Applied Precision has filed 16 patents.

The 3 most popular patent topics include:

  • Microscopes
  • Microscopy
  • Nanotechnology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/31/2017

10/13/2020

Microscopy, Microscopes, Scanning probe microscopy, Nanotechnology, Spectroscopy

Grant

Application Date

7/31/2017

Grant Date

10/13/2020

Title

Related Topics

Microscopy, Microscopes, Scanning probe microscopy, Nanotechnology, Spectroscopy

Status

Grant

Latest Applied Precision News

Oracle BrandVoice: Healthcare Researchers Crunch Genetic Data And Build Businesses on Oracle Cloud

Feb 19, 2019

Healthcare Researchers Crunch Genetic Data And Build Businesses on Oracle Cloud BRANDVOICE Share to linkedin Since the first sequencing of the human genome in 2003, people in the medical field have been working on ways to use a person’s unique genetic information to tailor treatments for the thorniest afflictions, from cancer to dementia to Parkinson’s, and many others. And it’s starting to work. Oracle New genetic tests look for mutations in DNA that can reveal tumors before they grow. And genetic targeting can make current therapies more effective by helping doctors understand whom they will work for and whom they won’t. For example, a new immunotherapy drugs for cancer might “work fabulously in about 20% of people,” says Richard Rendell, managing director at Applied Precision Medicine . His firm is helping a client build a test to find those 20%—sparing the other 80% for whom it won’t work, and saving the tens or even hundreds of thousands of dollars that a round of therapy can cost. Needless to say, doctors, patients and insurance companies want more. So lots of groups, from university scientists to startups to big pharmaceutical companies are working to develop such tests. But the road from designing a genetic test or therapy to using it to help patients is long and steep, with one of the first barriers being the mountain of data contained in the genomes they seek to study. “DNA data is enormous,” Rendell says. “We have the potential of generating almost a terabyte per person from their DNA. Depending on the analysis, data sets can run into a petabyte for just 1200 patients." Richard Rendell is managing director at Applied Precision Medicine. Courtesy of Applied Precision Medicine Rendell founded Applied Precision Medicine in 2012 as a consultancy focused on the technical implementation needed to quickly analyze that data, and provide advice on how to bring a genetic test or treatment to market. “We work with incredibly brilliant people in the medical and scientific field, but large-scale data management and building a business aren’t what they’re good at,” says Rendell. “They’ve developed an algorithm for working with genetic data in their lab and then we put it into a solid clinical-grade infrastructure” to build a viable business. That involves designing a path to clean data and effectively test their ideas, then getting approval from regulatory bodies like the FDA, and eventually building a business. Luckily, as genome sequencing and its medical possibilities matured, another technology also has been maturing. Cloud computing services enabled a company or a university to quickly access the needed computing power to run their algorithm or test their therapy against the three billion of base pairs, often around 700GB of data, in each person’s genetic code. Rendell has been there since the beginning. In the early 2000s, he was working as an IT architect: “I get a call one day to support this rather odd-looking data, which was all ACG’s and T’s, and there was a hell of a lot of them.” That was his introduction genomic data. Over time Rendell grew an expertise in helping scientific and clinical organizations wrangle their data while learning as he went about their longer-term goals and struggles, which led him to start his own business. Applied Precision Medicine started off using Amazon AWS to manage this data for clinical customers. But it switched to Oracle Cloud because, says Rendell, along with Oracle’s years of data experience in healthcare, its platform more closely maps to what is needed to grow a business, including regulatory compliance and commercialization of treatments. Oracle Innovation Management Cloud and Oracle Product Lifecycle Management Cloud “gives us more comprehensive control beyond just a quality management system,” because regulators want to see the total product lifecycle, he says. And Oracle has the best e-clinical trial platform with its recent purchase of goBalto , he notes. “We then can leverage Oracle Cloud for Healthcare ,” which brings together ERP, finance, HCM, supply chain, patient management, and analytics. “We’re able to help our customers with not only the implementation of their therapy or device, but also the management of it at the clinical and commercial level,” Rendell says. “All of those things we can provide by simply spinning up those services in Oracle cloud.” Many times, the Oracle database and applications are “the same ones their customers—the pharma companies, the big med device companies—are using,” he says. “That gives our customers the ability to say, ‘We're on Oracle, so it'll be a very easy thing for us to do a collaboration,’ and that opens a conversation.” All About the Data But first the client companies have to get the data right. Easier said than done. “A pathology lab will do the sequencing of the bio sample and spit out a huge amount of data,” says Rendell. It can be XML, it can be JSON, it can be CSV, or any of 40-plus file formats specific to genomics. “And it can be horribly formatted, but it’s got really critical genomic data in it.” Depending on what the researcher needs, the genetic data can get “mixed with other registries or patient-generated data, such as those from a cardiac device and even your mobile device.” In the end, the core data needs to be clean, with all sensitive data extracted and presented in a way that helps the researcher answer his or her question, and then confidently share it. “Once you gather that data, the question is, how does that become real-world evidence for the FDA and potential customers in the healthcare industry?” Rendell says. One technology in Oracle Cloud that Rendell and his team are bringing into their newest projects is Oracle Autonomous Database , a new database technology that provisions, tunes, secures, and scales as needed with no human intervention. “When we're not spending time on all those things, we're investing more in working alongside researchers and clinicians to improve people's lives,” Rendell says. The autonomous database means less human error in the basic setup and management of the database, which leads to “better device safety, better patient data security,” he says. Plus, Oracle’s autonomous database “is robust. It's going to be accepted by the customers of our customers, because many of them are built on Oracle.” It’s another example, he says, of “so many tools in Oracle Cloud that we can spin up. We can just turn them on and get working on delivering outcomes.” Rendell cites the universal credit program in Oracle Cloud as a great way to quickly try out new apps and technologies, since funds from a single budget can be shifted around to any Oracle cloud service that’s needed for a project; “I have used the program heavily in the last six months to do proof of concepts.” One ambitious new project for Rendell and Applied Precision Medicine is to provide a data sharing platform for the genomic research industry—one that would give researchers and startups access to the tons of clinical trial data generated by big pharmaceutical companies in a way that’s beneficial to both, and protects each one’s intellectual property. “The pharma company doesn't get access to the source code of the smaller company, and the smaller company cannot download the trial data, Rendell says. “It all happens inside the platform” on Oracle Cloud. “It's a much cheaper and easier way for the pharma companies to be in touch and share their data with some of these newer companies,” he says, which “ultimately will result in better drugs or better application of the drugs and better outcomes for more people.” And that, Rendell reminds us, is the name of the game.

  • When was Applied Precision founded?

    Applied Precision was founded in 1986.

  • Where is Applied Precision's headquarters?

    Applied Precision's headquarters is located at 1040 12th Avenue Northwest, Issaquah.

  • What is Applied Precision's latest funding round?

    Applied Precision's latest funding round is Acquired.

  • How much did Applied Precision raise?

    Applied Precision raised a total of $24M.

  • Who are the investors of Applied Precision?

    Investors of Applied Precision include GE Healthcare, Telegraph Hill Partners, Riverside Partners and Landmark Partners.

  • Who are Applied Precision's competitors?

    Competitors of Applied Precision include LifeSensors, Quanterix, Sword Diagnostics, NMS Group, Pronota and 9 more.

You May Also Like

G
Genomic Solutions

The scientists at Genomic Solutions have a wealth of genomic, protein analysis and nano-liter dispensing application-based expertise that they would like to share with users. First select their area of research, followed by interest and then application, and finally, to the company's instrumentation which can help facilitate their research. Whether users are involved in the life science or biotechnology research community, the company's products will enable users to perform complex, high volume experiments at a lower cost and in less time than traditional techniques. You achieve rapid and less expensive drug discovery.

S
Sword Diagnostics

Sword Diagnostics is a life sciences company created in response to the needs of the research, pharmaceutical, and clinical communities. Although researchers are discovering thousands of biomarkers associated with both healthy and diseased-related biological processes, today's life science tools are unable to effectively measure, quantify, and determine the ultimate value of these biological markers. Sword Diagnostics' technology is directly aimed at making it easier to understand these newly emerging biomarkers, as well as extending the utility of existing diagnostics assays. Sword's mission is to provide the next-generation detection technology to life scientists, enabling them to continue advances in medical research, drug discovery and the provision of health care products and services.

A
Anthill Technologies

Anthill Technologies, Inc. is pioneering the development and commercialization of a unique proprietary applied chemistry operating system (ACOS�) and a novel high-speed chemical discovery engine based on this operating system to dramatically reduce the time, cost and risk factors associated with discovering and developing chemical compositions, pathways, processes and products for applications in both life science and non-life science markets.

Fluxion Biosciences Logo
Fluxion Biosciences

Fluxion Biosciences is a developer of precision solutions for life science research and diagnostics. Fluxion's liquid biopsy solutions are changing how cancer is detected and treated. Fluxion's pioneering liquid biopsy technologies include the IsoFlux CTC Liquid Biopsy System, ERASE-Seq ultra-sensitive variant caller, and the Spotlight 59 NGS Oncology Panel for cancer mutation detection from cell-free circulating tumor DNA. Fluxion's technologies are used globally by cancer centers developing new tests for early cancer detection and patient monitoring.

P
PlexPress

PlexPress is a life science company doing work in gene expression analysis technology to advance biological science, drug discovery, crop science and diagnostics. PlexPress seeks to rapidly provide reliable information at low cost. Its products simultaneously measure multiple genes from multiple samples. PlexPress operates from Los Altos, California and Helsinki, Finland.

V
Vivonetics

Vivonetics a company created through Georgia Tech's VentureLab program. The company is developing applications for molecular beacon technology in life science research and drug discovery. Its initial focus is on probes to detect RNA in living cells.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.